Palvella Therapeutics, Inc. Accounts Payable and Other Accrued Liabilities, Current
Palvella Therapeutics, Inc. (PVLA) had Accounts Payable and Other Accrued Liabilities, Current of $10.79 million as of 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2022-08-04
- 2022-06-30: Accounts Payable and Other Accrued Liabilities, Current $10.79M.
- 2022-03-31: Accounts Payable and Other Accrued Liabilities, Current $14.07M.
- 2021-12-31: Accounts Payable and Other Accrued Liabilities, Current $16.84M.
- 2021-09-30: Accounts Payable and Other Accrued Liabilities, Current $19.68M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2022-06-30 | $10.79M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $14.07M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $16.84M 10-Q · filed 2022-08-04 |
| 2021-09-30 | $19.68M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $16.08M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $9.56M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $7.73M 10-K · filed 2022-03-02 |
| 2020-09-30 | $7.49M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $5.94M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $6.94M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $9.94M 10-K · filed 2021-03-31 |
| 2019-09-30 | $7.17M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $8.49M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $9.22M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $9.11M 10-K · filed 2020-03-13 |
| 2018-09-30 | $5.98M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $4.56M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $6.58M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $6.17M 10-K · filed 2019-03-18 |
| 2016-12-31 | $3.72M 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |